Repare Therapeutics Inc
RPTX2.650USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
113.91MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Repare Therapeutics Inc Unternehmen
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc Informationen
BörsenkürzelRPTX
Name des UnternehmensRepare Therapeutics Inc
IPO-datumJun 19, 2020
CEOForte (Steve)
Anzahl der mitarbeiter129
WertpapierartOrdinary Share
GeschäftsjahresendeJun 19
Addresse7210 Frederick-Banting, Suite 100
StadtST-LAURENT
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlH4S 2A1
Telefon18574127018
Websitehttps://www.reparerx.com/
BörsenkürzelRPTX
IPO-datumJun 19, 2020
CEOForte (Steve)
Führungskräfte von Repare Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-18800.00%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-8000.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-4000.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-7500.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-18800.00%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-8000.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
Switzerland
11.62M
0.00%
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
Andere
71.82%
Aktionäre
Aktionäre
Anteil
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
Andere
71.82%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
12.13%
Investment Advisor/Hedge Fund
11.03%
Investment Advisor
8.95%
Private Equity
7.51%
Individual Investor
0.31%
Venture Capital
0.31%
Research Firm
0.17%
Family Office
0.09%
Andere
59.51%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
116
24.72M
57.35%
-9.60M
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Blue Owl Capital Holdings LP
3.37M
7.82%
-71.16K
-2.07%
Nov 21, 2025
OrbiMed Advisors, LLC
3.20M
7.42%
-124.40K
-3.74%
Nov 21, 2025
Redmile Group, LLC
1.59M
3.68%
--
--
Sep 30, 2025
MPM Capital Inc.
1.12M
2.6%
--
--
Sep 30, 2025
MPM BioImpact LLC
819.92K
1.9%
--
--
Sep 30, 2025
Renaissance Technologies LLC
724.16K
1.68%
+201.30K
+38.50%
Sep 30, 2025
Citadel Advisors LLC
699.30K
1.62%
-238.19K
-25.41%
Sep 30, 2025
Rangeley Capital LLC
645.88K
1.5%
+290.58K
+81.79%
Sep 30, 2025
Acadian Asset Management LLC
568.30K
1.32%
-112.88K
-16.57%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Avantis US Equity ETF
Anteil0%
SPDR S&P International Small Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
